Mackenzie Financial Corp Has $2.09 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Mackenzie Financial Corp lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 55.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,859 shares of the biopharmaceutical company's stock after selling 10,832 shares during the quarter. Mackenzie Financial Corp's holdings in Alnylam Pharmaceuticals were worth $2,085,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. Larson Financial Group LLC lifted its stake in Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 73 shares during the last quarter. R Squared Ltd bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $33,000. OFI Invest Asset Management acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $35,000. Colonial Trust Co SC bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $35,000. Finally, IFP Advisors Inc raised its stake in Alnylam Pharmaceuticals by 24.2% during the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 47 shares during the period. Institutional investors own 92.97% of the company's stock.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the sale, the chief executive officer now directly owns 48,948 shares of the company's stock, valued at approximately $14,978,088. The trade was a 28.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently commented on ALNY. Morgan Stanley lowered their target price on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a report on Friday, April 11th. William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their target price for the company from $280.00 to $328.00 in a research note on Monday, March 24th. HC Wainwright restated a "buy" rating and set a $500.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Finally, Canaccord Genuity Group increased their price objective on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a report on Friday, March 21st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $319.17.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY traded up $1.54 during mid-day trading on Wednesday, hitting $305.31. 563,088 shares of the company's stock traded hands, compared to its average volume of 930,176. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 12 month low of $147.25 and a 12 month high of $308.93. The firm has a 50 day moving average of $262.51 and a two-hundred day moving average of $256.16. The firm has a market capitalization of $39.81 billion, a price-to-earnings ratio of -140.70 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. The company's revenue for the quarter was up 20.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.16) EPS. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.